CareCloud (CCLD)
Market Price (11/10/2026): $2.52 | Market Cap: $107.2 MilSector: Health Care | Industry: Health Care Technology
CareCloud (CCLD)
Market Price (11/10/2026): $2.52Market Cap: $107.2 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.7%, FCF Yield is 17% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% Megatrend and thematic driversMegatrends include Cloud Computing, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Telehealth Platforms, Show more. | Weak multi-year price returns2Y Excs Rtn is -24% | Key risksCCLD key risks include [1] the potential forced resignation of its public accounting firm and [2] geopolitical instability impacting its substantial operations in Pakistan and Sri Lanka. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 9.0%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.7%, FCF Yield is 17% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 19%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Megatrend and thematic driversMegatrends include Cloud Computing, and Digital Health & Telemedicine. Themes include Software as a Service (SaaS), Telehealth Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -24% |
| Key risksCCLD key risks include [1] the potential forced resignation of its public accounting firm and [2] geopolitical instability impacting its substantial operations in Pakistan and Sri Lanka. |
Qualitative Assessment
AI Analysis | Feedback
Nov 9: up 9.1% in one day (S&P 500 up 2.4%)
CareCloud shares rose without company-specific news. This occurred on a day when the broader market staged a broad-based relief rally, with the S&P 500 also closing higher.
Up 46.8% since its Oct 26 low (S&P 500 down 1.7%)
The strong increase was primarily driven by the positive reaction to the company's fiscal third quarter 2026 earnings report. The largest daily gains occurred on November 5 following the earnings, and November 9 during a broad market rally.
Nov 5: up 20.0% on its earnings report (S&P 500 down 4.4%)
CareCloud's stock surged after reporting strong fiscal third quarter 2026 results. Revenue increased 9% and net income grew 54%, while diluted EPS rose 150% compared to a year earlier.
Nov 9: up 9.1% in one day (S&P 500 up 2.4%)
CareCloud shares rose without company-specific news. This occurred on a day when the broader market staged a broad-based relief rally, with the S&P 500 also closing higher.
Up 46.8% since its Oct 26 low (S&P 500 down 1.7%)
The strong increase was primarily driven by the positive reaction to the company's fiscal third quarter 2026 earnings report. The largest daily gains occurred on November 5 following the earnings, and November 9 during a broad market rally.
Nov 5: up 20.0% on its earnings report (S&P 500 down 4.4%)
CareCloud's stock surged after reporting strong fiscal third quarter 2026 results. Revenue increased 9% and net income grew 54%, while diluted EPS rose 150% compared to a year earlier.
Show less
Stock Movement Drivers
Fundamental Drivers
The 2.9% change in CCLD stock from 7/31/2026 to 11/9/2026 was primarily driven by a 5.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312026 | 11092026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.44 | 2.51 | 2.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 124 | 131 | 5.8% |
| Net Income Margin (%) | 7.9% | 7.4% | -6.5% |
| P/E Multiple | 10.6 | 11.1 | 4.2% |
| Shares Outstanding (Mil) | 42 | 43 | -0.1% |
| Cumulative Contribution | 2.9% |
Market Drivers
7/31/2026 to 11/9/2026| Return | Correlation | |
|---|---|---|
| CCLD | 2.9% | |
| Market (SPY) | 0.8% | 0.1% |
| Sector (XLV) | 15.9% | -2.3% |
Fundamental Drivers
The -16.9% change in CCLD stock from 4/30/2026 to 11/9/2026 was primarily driven by a -17.9% change in the company's Net Income Margin (%).| (LTM values as of) | 4302026 | 11092026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.02 | 2.51 | -16.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 120 | 131 | 9.0% |
| Net Income Margin (%) | 9.0% | 7.4% | -17.9% |
| P/E Multiple | 11.9 | 11.1 | -6.9% |
| Shares Outstanding (Mil) | 42 | 43 | -0.2% |
| Cumulative Contribution | -16.9% |
Market Drivers
4/30/2026 to 11/9/2026| Return | Correlation | |
|---|---|---|
| CCLD | -16.9% | |
| Market (SPY) | 5.0% | 4.2% |
| Sector (XLV) | 29.6% | 6.1% |
Fundamental Drivers
The -14.9% change in CCLD stock from 10/31/2025 to 11/9/2026 was primarily driven by a -27.0% change in the company's Net Income Margin (%).| (LTM values as of) | 10312025 | 11092026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.95 | 2.51 | -14.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 112 | 131 | 17.4% |
| Net Income Margin (%) | 10.1% | 7.4% | -27.0% |
| P/E Multiple | 11.1 | 11.1 | -0.3% |
| Shares Outstanding (Mil) | 42 | 43 | -0.5% |
| Cumulative Contribution | -14.9% |
Market Drivers
10/31/2025 to 11/9/2026| Return | Correlation | |
|---|---|---|
| CCLD | -14.9% | |
| Market (SPY) | 11.3% | 9.1% |
| Sector (XLV) | 32.2% | 5.9% |
Fundamental Drivers
The 169.9% change in CCLD stock from 10/31/2023 to 11/9/2026 was primarily driven by a 603.2% change in the company's P/S Multiple.| (LTM values as of) | 10312023 | 11092026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.93 | 2.51 | 169.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 126 | 131 | 4.5% |
| P/S Multiple | 0.1 | 0.8 | 603.2% |
| Shares Outstanding (Mil) | 16 | 43 | -63.3% |
| Cumulative Contribution | 169.9% |
Market Drivers
10/31/2023 to 11/9/2026| Return | Correlation | |
|---|---|---|
| CCLD | 169.9% | |
| Market (SPY) | 86.2% | 15.6% |
| Sector (XLV) | 58.4% | 7.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CCLD Return | -30% | -56% | -46% | 141% | -20% | -14% | -72% |
| Peers Return | -38% | -47% | -19% | -33% | -27% | 25% | -84% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 96% |
Monthly Win Rates [3] | |||||||
| CCLD Win Rate | 42% | 17% | 50% | 50% | 50% | 27% | |
| Peers Win Rate | 34% | 35% | 47% | 40% | 30% | 51% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| CCLD Max Drawdown | -59% | -60% | -83% | -53% | -74% | -55% | |
| Peers Max Drawdown | -61% | -67% | -57% | -55% | -55% | -42% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: PHR, TDOC, AMWL, HCAT, PRVA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/9/2026 (YTD)
How Low Can It Go
| Event | CCLD | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -74.2% | -9.5% |
| % Gain to Breakeven | 288.0% | 10.5% |
| Time to Breakeven | 160 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.2% | -6.7% |
| % Gain to Breakeven | 41.3% | 7.1% |
| Time to Breakeven | 552 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.8% | -33.7% |
| % Gain to Breakeven | 84.6% | 50.9% |
| Time to Breakeven | 78 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -35.4% | -19.2% |
| % Gain to Breakeven | 54.7% | 23.8% |
| Time to Breakeven | 119 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -56.2% | -3.7% |
| % Gain to Breakeven | 128.2% | 3.9% |
| Time to Breakeven | 13 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -65.7% | -12.2% |
| % Gain to Breakeven | 191.3% | 13.9% |
| Time to Breakeven | 419 days | 62 days |
In The Past
CareCloud's stock fell -7.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 8.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | CCLD | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -74.2% | -9.5% |
| % Gain to Breakeven | 288.0% | 10.5% |
| Time to Breakeven | 160 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -29.2% | -6.7% |
| % Gain to Breakeven | 41.3% | 7.1% |
| Time to Breakeven | 552 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -45.8% | -33.7% |
| % Gain to Breakeven | 84.6% | 50.9% |
| Time to Breakeven | 78 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -35.4% | -19.2% |
| % Gain to Breakeven | 54.7% | 23.8% |
| Time to Breakeven | 119 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -56.2% | -3.7% |
| % Gain to Breakeven | 128.2% | 3.9% |
| Time to Breakeven | 13 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -65.7% | -12.2% |
| % Gain to Breakeven | 191.3% | 13.9% |
| Time to Breakeven | 419 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -74.0% | -6.8% |
| % Gain to Breakeven | 284.0% | 7.3% |
| Time to Breakeven | 619 days | 15 days |
In The Past
CareCloud's stock fell -7.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 8.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About CareCloud (CCLD)
CareCloud, Inc. (CCLD) is a healthcare information technology (IT) company that provides a suite of cloud-based solutions and related business services. Operating primarily in the United States, CareCloud focuses on enhancing the operational and clinical efficiency of healthcare providers and hospitals through its two core segments: Healthcare IT and Practice Management.
The company offers a comprehensive Software-as-a-Service (SaaS) platform that includes essential tools for modern medical practices. Key solutions provided are revenue cycle management, practice management, and electronic health record (EHR) systems. Beyond these foundational services, CareCloud's platform also incorporates business intelligence, telehealth capabilities, and patient experience management solutions, alongside various other complementary software tools and business services.
CareCloud's primary market consists of a broad spectrum of healthcare professionals and organizations. Its services are utilized by individual physicians, nurses, nurse practitioners, physician assistants, and other clinicians who bill for their services, as well as larger medical groups and health systems across the U.S.
AI Analysis | Feedback
Salesforce for Healthcare
Shopify for Doctor's Offices
AI Analysis | Feedback
- Revenue Cycle Management: Solutions for managing the financial processes of healthcare providers, from patient registration to payment collection.
- Practice Management: Software and services designed to help healthcare practices manage administrative and operational tasks efficiently.
- Electronic Health Record (EHR): Cloud-based software for secure and comprehensive management of patient medical information.
- Business Intelligence: Tools and services that provide data analytics and insights to improve healthcare operations and outcomes.
- Telehealth: Platforms and services enabling remote healthcare consultations and patient monitoring.
- Patient Experience Management: Solutions focused on enhancing patient engagement, satisfaction, and overall experience with healthcare services.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Stephen Snyder, Chief Executive Officer
Stephen Snyder was appointed Chief Executive Officer of CareCloud, Inc. effective January 1, 2026. In this role, he focuses on disciplined execution, financial performance, margin expansion, and scaling CareCloud’s AI-enabled solutions across both ambulatory and hospital markets.
Norman Roth, Interim Chief Financial Officer and Corporate Controller
Norman Roth serves as CareCloud's Interim CFO and Corporate Controller, bringing over 40 years of financial expertise. He joined CareCloud in 2014, and before that, he worked as a forensic accountant since 2003, specializing in accounting malpractice. From 1991 to 2002, Mr. Roth was the Director of External Reporting, Treasury and Tax, and later Business Manager at WWOR-TV. He began his career at Ernst & Young LLP in 1977, serving for 13 years as a senior manager.
A. Hadi Chaudhry, Chief Strategy Officer
A. Hadi Chaudhry transitioned to Chief Strategy Officer effective January 1, 2026, where he leads CareCloud's enterprise AI vision, platform innovation, and company-wide artificial intelligence initiatives. Previously, he served as the company's CEO and President. Mr. Chaudhry joined CareCloud, then known as MTBC, in October 2002 as an IT Manager. He progressively advanced through various roles, becoming Vice President of Global Operations in 2016, and then President and CEO in 2018. He possesses extensive healthcare IT experience, having also held various positions in the banking and IT sectors prior to joining CareCloud.
Mahmud Haq, Founder & Executive Chairman
Mahmud Haq is the Founder and Executive Chairman of CareCloud. He founded the company, originally known as Medical Transcription Billing Corporation (MTBC), in 1999, and has been instrumental in shaping its success.
Crystal Williams, Chief Operating Officer
Crystal Williams holds the title of Chief Operating Officer at CareCloud.
AI Analysis | Feedback
The key risks to CareCloud, Inc. (CCLD) primarily stem from its growth strategy and the dynamic healthcare technology landscape:
- Acquisition Strategy and Organic Revenue Decline: CareCloud's aggressive acquisition strategy, while driving growth, has been noted by analysts as potentially masking a decline in underlying organic revenues. Furthermore, there are significant risks associated with integrating acquired businesses, including operational disruptions, unexpected financial burdens, and the potential for further impairment of goodwill.
- Share Dilution: The company faces ongoing risks related to share dilution. A notable event was the conversion of the majority of its Series A Preferred Stock into common stock in March 2025, which increased the total number of outstanding shares and potentially diluted the value of existing common shareholders' equity. Future equity raises or additional acquisitions funded by equity could further exacerbate this dilution.
- Regulatory Changes and Geopolitical Risks: CareCloud is exposed to sector-specific risks, particularly regulatory changes within the healthcare industry. Emerging 2026 state AI regulations, for example, could limit the adoption of CareCloud's new AI-driven solutions. Additionally, the company's heavy reliance on significant offshore operations in Pakistan and Sri Lanka for its cost advantage introduces geopolitical and operational risks that could impact its business, financial condition, and results of operations.
AI Analysis | Feedback
The clear emerging threat to CareCloud (CCLD) is the aggressive expansion of large, well-capitalized technology companies into the healthcare IT and service delivery sectors. Companies such as Amazon, Google, and Microsoft are leveraging their extensive resources, advanced artificial intelligence and cloud computing capabilities, and established integrated ecosystems to develop and offer comprehensive healthcare solutions. These offerings could span electronic health records, practice management, revenue cycle management, and telehealth, directly competing with and potentially disrupting CareCloud's specialized suite of services. The threat stems from these tech giants' ability to build highly integrated, scalable, and potentially more cost-effective solutions, or to acquire and consolidate existing healthcare IT providers, fundamentally altering the competitive landscape for specialized vendors.
AI Analysis | Feedback
CareCloud, Inc. (CCLD) operates in several significant healthcare information technology markets within the United States. The addressable market sizes for its main products and services are as follows:
-
Revenue Cycle Management (RCM): The U.S. healthcare revenue cycle management market was estimated at USD 172.24 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 10.1% from 2025 to 2030. Other estimates for the U.S. market include a size of USD 65.38 billion in 2025, reaching approximately USD 195.92 billion by 2035 with a CAGR of 11.6% from 2026 to 2035.
-
Practice Management (PM): The U.S. practice management system market size was estimated at USD 5.89 billion in 2024 and is projected to reach USD 13.70 billion by 2033, growing at a CAGR of 10.03% from 2025 to 2033. Another report indicates the U.S. practice management system market size was USD 6.65 billion in 2025 and is projected to reach around USD 16.38 billion by 2035, with a CAGR of 9.43% from 2026 to 2035.
-
Electronic Health Record (EHR): The U.S. electronic health records market size was estimated at USD 12.87 billion in 2024 and is projected to grow at a CAGR of 2.55% from 2025 to 2030. Another source reported the U.S. EHR market size as USD 13.7 billion in 2023. The USA EHR market is projected to grow from USD 10.1 billion in 2025 to USD 16.9 billion by 2035, at a CAGR of 5.3%.
-
Business Intelligence (BI) for Healthcare: The U.S. healthcare business intelligence market generated a revenue of USD 4,193.9 million in 2024 and is expected to reach USD 8,850.1 million by 2030. North America's healthcare business intelligence market accounted for USD 2.6 billion in revenue in 2023.
-
Telehealth: The U.S. telehealth market size was estimated at USD 52.77 billion in 2025 and is anticipated to increase to USD 65.35 billion in 2026. By 2035, it is forecasted to reach approximately USD 447.69 billion, growing at a CAGR of 23.84%. Other estimates for the U.S. telehealth market include USD 66.75 billion in 2025, expected to reach USD 198.77 billion by 2030 at a CAGR of 24.39%.
-
Patient Experience Management Solutions: The U.S. patient engagement solutions market size was valued at USD 7.59 billion in 2024 and is expected to grow at a CAGR of 19.77% from 2025 to 2030. Another projection for the U.S. patient engagement solutions market is USD 14.55 billion in 2025, reaching USD 25.01 billion by 2030, with a CAGR of 11.4%.
AI Analysis | Feedback
CareCloud, Inc. (CCLD) is expected to drive future revenue growth over the next two to three years through several key initiatives:
- Expansion of AI-Driven Solutions and New Product Launches: CareCloud is significantly investing in artificial intelligence (AI) with the launch of its AI Center of Excellence and new AI-powered products such as stratusAI Front Desk Agent, stratusAI Voice Audit, and cirrusAI Notes. These solutions aim to automate administrative and clinical workflows, enhance operational efficiency, and provide new offerings that are anticipated to unlock scalable and cost-efficient solutions, thereby expanding market reach and creating new revenue streams. The stratusAI Front Desk Agent, for instance, has already shown potential by automating a significant percentage of inbound scheduling calls for at least one client.
- Strategic Acquisitions and Expansion into the Inpatient Hospital Market: The company has strategically completed several acquisitions, including Medsphere Systems Corporation and MAP App in 2025. These acquisitions have expanded CareCloud's presence into the inpatient hospital market, adding new products such as inpatient electronic health records (EHR) and revenue cycle management (RCM) solutions, along with hospital benchmarking and analytics capabilities. This broadens their total addressable market and creates new opportunities for revenue generation by serving a wider array of healthcare providers.
- Cross-Selling and Upselling Enhanced Products to an Expanded Customer Base: With the integration of AI capabilities into acquired platforms and the expansion of its product portfolio, CareCloud anticipates substantial cross-sell opportunities across its growing client roster. The company's strategy is to leverage its AI expertise to make every acquired platform smarter, faster, and more valuable, driving adoption of its comprehensive suite of solutions among both existing and new customers.
AI Analysis | Feedback
Share Issuance
- CareCloud completed a conversion of the majority of its Series A Preferred Stock into common stock in March 2025, which increased the total number of outstanding shares.
- The number of common shares outstanding significantly increased from 16,256,236 at December 31, 2024, to 42,437,949 at December 31, 2025.
- Approximately 135,000 common shares were issued in February 2023 for employee bonuses that were originally planned as cash payments.
Outbound Investments
- In late 2025, CareCloud completed two strategic acquisitions to expand into the inpatient software market, which were funded entirely from operating cash flow.
- One of the significant acquisitions in August 2025 was Medsphere, an inpatient and ambulatory IT platform providing electronic health records, revenue cycle management, supply chain management, and managed IT services.
- These acquisitions, including Medsphere and Map App, broadened CareCloud's product portfolio by adding inpatient EHR, RCM, and a top-ranked EDIS platform, expanding the company's addressable market.
Capital Expenditures
- CareCloud invested $869,000 in capital expenditures in Q3 2025.
- Research and development expense increased by 69% in 2025, as the company expanded offshore headcount and capitalized software development efforts, indicating a focus on platform investment.
- Free cash flow, representing cash available after capital expenditures, reached $20.3 million in 2025, up from $13.2 million in 2024 and $3.8 million in 2023.
Peer Outperformance in Health Care Technology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 9.8% | 58.5% | 102.8% | CAH 516% · MCK 395% · COR 192% |
| Health Care Services | 20 | 34.0% | 25.5% | 10.9% | HIMS 177% · RDNT 147% · DGX 101% |
| Managed Health Care | 8 | 52.2% | -4.3% | -3.7% | OSCR 98% · HQY 50% · ELV 5% |
| Health Care Facilities | 26 | 23.0% | 20.7% | -4.3% | THC 263% · NHC 228% · EHC 190% |
| Health Care Equipment | 50 | 11.7% | 22.1% | -13.2% | UFPT 383% · GKOS 358% · TMDX 202% |
| Pharmaceuticals | 59 | -11.8% | 20.4% | -37.9% | LQDA 1097% · XERS 709% · KNSA 590% |
| Health Care Supplies | 11 | 29.2% | 20.4% | -40.8% | LNTH 235% · HAE 96% · MMSI 30% |
| Life Sciences Tools & Services | 109 | -0.8% | -9.6% | -74.3% | AXGN 278% · MEDP 201% · NTRA 183% |
| Biotechnology | 365 | -21.2% | -29.6% | -80.6% | ELVN 1218% · TRVI 1187% · DNTH 1113% |
| Health Care Technology ← | 21 | -19.4% | -44.4% | -82.6% | VEEV -4% · DOCS -57% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| CareCloud Earnings Notes | 12/16/2025 | |
| Is CareCloud Stock Built to Withstand a Pullback? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.13 |
| Mkt Cap | 0.5 |
| Rev LTM | 390 |
| Op Inc LTM | -8 |
| FCF LTM | 43 |
| FCF 3Y Avg | 20 |
| CFO LTM | 59 |
| CFO 3Y Avg | 36 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.3% |
| Rev Chg 3Y Avg | 0.8% |
| Rev Chg Q | 2.6% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Inc Chg LTM | 43.8% |
| Op Inc Chg 3Y Avg | 44.8% |
| Op Mgn LTM | -1.6% |
| Op Mgn 3Y Avg | -8.1% |
| QoQ Delta Op Mgn LTM | 1.1% |
| CFO/Rev LTM | 10.4% |
| CFO/Rev 3Y Avg | 7.6% |
| FCF/Rev LTM | 4.8% |
| FCF/Rev 3Y Avg | 4.8% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Healthcare Information Technology (IT) | 107 | 96 | 104 | 125 | 127 |
| Medical Practice Management | 14 | 14 | 13 | 14 | 13 |
| Unallocated Corporate Expenses | 0 | ||||
| Total | 120 | 111 | 117 | 139 | 140 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Healthcare Information Technology (IT) | 18 | 13 | -39 | 15 | 12 |
| Medical Practice Management | -0 | 1 | 1 | 1 | 0 |
| Unallocated Corporate Expenses | -6 | -5 | -9 | -9 | -8 |
| Total | 11 | 9 | -47 | 7 | 4 |
Price Behavior
| Market Price | $2.51 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 07/23/2014 | |
| Distance from 52W High | -34.1% | |
| 50 Days | 200 Days | |
| DMA Price | $2.01 | $2.46 |
| DMA Trend | down | down |
| Distance from DMA | 25.0% | 2.1% |
| 3M | 1YR | |
| Volatility | 70.4% | 63.9% |
| Downside Capture | 105.17 | 165.60 |
| Upside Capture | 99.00 | 99.02 |
| Correlation (S&P 500) | -16.1% | 9.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.01 | 1.84 | 1.96 | 1.06 | 0.87 | 1.19 |
| Up Beta | -7.01 | -0.66 | -0.37 | -0.14 | 0.77 | 0.97 |
| Down Beta | 1.59 | 2.21 | 0.61 | -0.16 | -0.51 | 1.22 |
| Up Capture | 150% | 114% | 220% | 109% | 94% | 193% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 9 | 14 | 23 | 51 | 103 | 329 |
| Down Capture | 318% | 282% | 323% | 207% | 143% | 106% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 10 | 22 | 33 | 66 | 136 | 386 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCLD | |
|---|---|---|---|---|
| CCLD | -27.8% | 63.9% | -0.26 | - |
| Sector ETF (XLV) | 30.8% | 17.0% | 1.40 | 6.1% |
| Equity (SPY) | 13.3% | 13.7% | 0.65 | 11.1% |
| Gold (GLD) | 3.7% | 28.8% | 0.12 | 5.1% |
| Commodities (DBC) | 38.2% | 21.3% | 1.42 | -15.9% |
| Real Estate (VNQ) | 13.7% | 14.3% | 0.65 | 14.4% |
| Bitcoin (BTCUSD) | -25.3% | 43.6% | -0.55 | 20.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCLD | |
|---|---|---|---|---|
| CCLD | -22.9% | 92.5% | 0.11 | - |
| Sector ETF (XLV) | 8.8% | 15.4% | 0.37 | 11.2% |
| Equity (SPY) | 11.8% | 17.3% | 0.51 | 19.4% |
| Gold (GLD) | 17.8% | 19.1% | 0.75 | 0.4% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | -0.9% |
| Real Estate (VNQ) | 1.5% | 18.9% | -0.03 | 17.9% |
| Bitcoin (BTCUSD) | 4.4% | 51.6% | 0.27 | 17.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CCLD | |
|---|---|---|---|---|
| CCLD | 11.0% | 109.3% | 0.49 | - |
| Sector ETF (XLV) | 12.6% | 16.8% | 0.62 | 9.8% |
| Equity (SPY) | 15.3% | 18.0% | 0.72 | 15.0% |
| Gold (GLD) | 12.1% | 16.5% | 0.60 | 1.0% |
| Commodities (DBC) | 7.6% | 18.1% | 0.33 | 1.8% |
| Real Estate (VNQ) | 6.1% | 20.7% | 0.25 | 11.3% |
| Bitcoin (BTCUSD) | 60.0% | 66.3% | 1.00 | 9.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 11/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2026 | 20.0% | ||
| 8/6/2026 | -8.7% | -3.5% | -11.8% |
| 5/7/2026 | -17.4% | -29.1% | -21.4% |
| 3/12/2026 | 9.4% | 34.2% | 1.5% |
| 11/6/2025 | 17.6% | 8.6% | 5.8% |
| 8/5/2025 | 0.0% | 7.6% | 53.4% |
| 5/6/2025 | 22.3% | 16.0% | 22.3% |
| 3/13/2025 | 0.0% | 3.1% | -21.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 9 | 9 |
| # Negative | 13 | 14 | 14 |
| Median Positive | 4.1% | 8.6% | 17.4% |
| Median Negative | -8.7% | -4.7% | -13.3% |
| Max Positive | 22.3% | 34.2% | 53.4% |
| Max Negative | -21.1% | -29.1% | -48.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/5/2026 | 20.0% | ||
| 8/6/2026 | -8.7% | -3.5% | -11.8% |
| 5/7/2026 | -17.4% | -29.1% | -21.4% |
| 3/12/2026 | 9.4% | 34.2% | 1.5% |
| 11/6/2025 | 17.6% | 8.6% | 5.8% |
| 8/5/2025 | 0.0% | 7.6% | 53.4% |
| 5/6/2025 | 22.3% | 16.0% | 22.3% |
| 3/13/2025 | 0.0% | 3.1% | -21.9% |
| 11/12/2024 | 21.5% | 6.9% | 51.3% |
| 5/14/2024 | -21.1% | 20.3% | 22.0% |
| 3/21/2024 | -6.7% | -0.8% | -4.2% |
| 11/2/2023 | 3.9% | 22.4% | 13.7% |
| 8/3/2023 | -11.4% | -26.9% | -48.1% |
| 5/4/2023 | -3.9% | 3.2% | -4.5% |
| 3/2/2023 | -2.8% | -0.3% | -6.7% |
| 11/3/2022 | -10.0% | -26.2% | -15.2% |
| 8/4/2022 | -11.5% | -12.7% | -16.8% |
| 5/9/2022 | -11.0% | -3.3% | 3.6% |
| 3/14/2022 | -8.6% | -1.4% | -10.2% |
| 11/4/2021 | 0.7% | -5.8% | -23.2% |
| 8/5/2021 | 0.8% | -3.3% | -4.8% |
| 5/6/2021 | 4.1% | -0.5% | 17.4% |
| 2/25/2021 | -3.4% | -8.0% | -14.8% |
| 12/10/2020 | -6.6% | -9.6% | -11.3% |
| SUMMARY STATS | |||
| # Positive | 11 | 9 | 9 |
| # Negative | 13 | 14 | 14 |
| Median Positive | 4.1% | 8.6% | 17.4% |
| Median Negative | -8.7% | -4.7% | -13.3% |
| Max Positive | 22.3% | 34.2% | 53.4% |
| Max Negative | -21.1% | -29.1% | -48.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/05/2026 | 10-Q |
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2026 | 11/05/2026 | 10-Q |
| 06/30/2026 | 08/06/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 03/13/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/13/2024 | 10-Q |
| 03/31/2024 | 05/14/2024 | 10-Q |
| 12/31/2023 | 03/21/2024 | 10-K |
| 09/30/2023 | 11/02/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 03/02/2023 | 10-K |
| 09/30/2022 | 11/03/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 03/14/2022 | 10-K |
| 09/30/2021 | 11/04/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/25/2021 | 10-K |
| 09/30/2020 | 11/09/2020 | 10-Q |
| 06/30/2020 | 08/13/2020 | 10-Q |
| 03/31/2020 | 05/14/2020 | 10-Q |
| 12/31/2019 | 02/28/2020 | 10-K |
Recent Forward Guidance
Updated 11/6/2026Latest: Q3 2026 Earnings Reported 11/5/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 128.00 Mil | 130.00 Mil | 132.00 Mil | 0.0% | Affirmed | Guidance: 130.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 29.00 Mil | 30.00 Mil | 31.00 Mil | 0.0% | Affirmed | Guidance: 30.00 Mil for 2026 | |
| 2026 Adjusted EBITDA Growth | Reported | 5.0% | 9.0% | 13.0% | ||||
| 2026 GAAP Net Income Per Share (EPS) | Reported | 0.2 | 0.22 | 0.23 | 0.0% | Affirmed | Guidance: 0.22 for 2026 | |
| 2026 GAAP EPS Growth | Reported | 100.0% | 115.0% | 130.0% | ||||
Prior: Q2 2026 Earnings Reported 8/6/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 128.00 Mil | 130.00 Mil | 132.00 Mil | 0 | Affirmed | Guidance: 130.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 29.00 Mil | 30.00 Mil | 31.00 Mil | 0 | Affirmed | Guidance: 30.00 Mil for 2026 | |
| 2026 GAAP Net Income Per Share (EPS) | Reported | 0.2 | 0.22 | 0.23 | 0 | Affirmed | Guidance: 0.22 for 2026 | |
Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 128.00 Mil | 130.00 Mil | 132.00 Mil | 0 | Affirmed | Guidance: 130.00 Mil for 2026 | |
| 2026 Adjusted EBITDA | Reported | 29.00 Mil | 30.00 Mil | 31.00 Mil | 0 | Affirmed | Guidance: 30.00 Mil for 2026 | |
| 2026 GAAP Net Income Per Share (EPS) | Reported | 0.2 | 0.22 | 0.23 | 0 | 0 | Affirmed | Guidance: 0.22 for 2026 |
Q4 2025 Earnings Reported 3/12/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 128.00 Mil | 130.00 Mil | 132.00 Mil | 10.2% | Higher New | Actual: 118.00 Mil for 2025 | |
| 2026 Adjusted EBITDA | Reported | 29.00 Mil | 30.00 Mil | 31.00 Mil | 11.1% | Higher New | Actual: 27.00 Mil for 2025 | |
| 2026 GAAP Net Income Per Share (EPS) | Reported | 0.2 | 0.22 | 0.23 | 87.0% | Higher New | Actual: 0.12 for 2025 | |
CareCloud — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Technology Resources |
| Healthcare IT News |
| MobiHealthNews |
| HealthTech Magazine |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.